北米の核医学/放射性医薬品市場：診断用（SPECT、PET）、治療用（ベータ放射体、アルファ放射体、小線源治療）...市場調査レポートについてご紹介

1 Introduction (Page No. – 19)
1.1 Objectives of Study
1.2 North American Radiopharmaceuticals Market Definition
1.3 North American Radiopharmaceuticals Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 Research Methodology (Page No. – 22)
2.1 Research Methodology Steps
2.2 Secondary and Primary Research Methodology
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.2.1 Key Industry Insights
2.2.2.2 Key Data From Primary Sources
2.2.2.3 Key Insights From Primary Sources
2.3 North American Radiopharmaceuticals Market Size Estimation Methodology
2.4 Research Design
2.5 North American Radiopharmaceuticals Market Data Validation and Triangulation
2.6 Assumptions for the Study

3 Executive Summary (Page No. – 31)
3.1 Introduction
3.2 Current Scenario
3.3 Future Outlook

4 Premium Insights (Page No. – 35)
4.1 North American Nuclear Medicine Market
4.2 North American Nuclear Medicine Diagnostic Market, By Therapeutic and Spect Application
4.3 North American Nuclear Medicine Market, By Country
4.4 North American Nuclear Medicine Market, By Type (2015 vs 2020)

5 Market Overview (Page No. – 39)
5.1 Introduction
5.2 North American Radiopharmaceuticals Market Segmentation
5.3 North American Radiopharmaceuticals Market Dynamics
5.3.1 Drivers
5.3.1.1 Increasing Preference for Spect and PET Scans
5.3.1.2 Alpha Radioimmunotherapy-Based Targeted Cancer Treatment
5.3.1.3 Advances in Radiotracers
5.3.1.4 Growing Incidence of Cancer and Cvds
5.3.1.5 Rising Awareness About the Effective Use of Radiopharmaceuticals in Various Applications
5.3.2 Restraints
5.3.2.1 Requirement of High Capital Investments to Limit the Procurement of Scanners
5.3.2.2 Shorter Half-Life of Radiopharmaceuticals
5.3.2.3 Stringent Regulatory Guidelines and Good Manufacturing Practices
5.3.2.4 Competition From Conventional Diagnostic Procedures
5.3.3 Opportunities
5.3.3.1 Upcoming Radioisotopes
5.3.3.2 Alternative Diagnostic Radiopharmaceutical Solutions
5.3.3.3 Cyclotron-Based Production
5.3.3.4 Use of Radiopharmaceuticals in Neurological Applications
5.3.4 Challenges
5.3.4.1 Shutdown of Nuclear Reactors to Impact Production of Radioisotopes

6 North American Nuclear Medicine Market: Pipeline Assessment (Page No. – 49)
6.1 Introduction
6.2 Diagnostic Radioisotopes
6.3 Therapeutic Radioisotopes

7 North American Nuclear Medicine Market, By Type (Page No. – 61)
7.1 Introduction
7.2 Diagnostic Nuclear Medicine/Radiopharmaceuticals
7.2.1 Spect Radiopharmaceuticals
7.2.1.1 Technetium-99m
7.2.1.2 Thallium-201
7.2.1.3 Gallium-67
7.2.1.4 Iodine-123
7.2.1.5 Other Spect Isotopes
7.2.2 PET Radiopharmaceuticals
7.2.2.1 Fluorine-18
7.2.2.2 Rubidium-82
7.2.2.3 Other PET Isotopes
7.3 Therapeutic Nuclear Medicine/Radiopharmaceuticals
7.3.1 Beta Emitters
7.3.1.1 Iodine-131
7.3.1.2 Yttrium-90
7.3.1.3 Samarium-153
7.3.1.4 Rhenium-186
7.3.1.5 Lutetium-177
7.3.1.6 Other Beta Emitter Isotopes
7.3.2 Alpha Emitters
7.3.2.1 Radium-223
7.3.3 Brachytherapy
7.3.3.1 Iodine-125
7.3.3.2 Iridium-192
7.3.3.3 Palladium-103
7.3.3.4 Cesium-131
7.3.3.5 Other Brachytherapy Isotopes

8 North American Nuclear Medicine Market, By Application (Page No. – 89)
8.1 Introduction
8.2 Diagnostic Applications
8.2.1 Spect Applications
8.2.1.1 Cardiology
8.2.1.2 Lymphoma
8.2.1.3 Neurology
8.2.1.4 Thyroid
8.2.1.5 Other Spect Applications
8.2.2 PET Applications
8.2.2.1 Oncology
8.2.2.2 Cardiology
8.2.2.3 Neurology
8.2.2.4 Other PET Applications
8.3 Therapeutic Applications
8.3.1 Thyroid
8.3.2 Bone Metastasis
8.3.3 Lymphoma
8.3.4 Endocrine Tumors
8.3.5 Other Therapeutic Applications

9 North American Nuclear Medicine Market for Procedural Volume (Page No. – 112)
9.1 Introduction
9.2 Diagnostic Nuclear Medicine/Radiopharmaceuticals Market for Procedural Volume
9.2.1 Spect Radiopharmaceuticals
9.2.2 PET Radiopharmaceuticals
9.3 Therapeutic Nuclear Medicine/Radiopharmaceuticals Market for Procedural Volume
9.3.1 Beta Emitters
9.3.2 Brachytherapy

10 North American Nuclear Medicine Market, By Country (Page No. – 118)
10.1 Introduction
10.2 Diagnostic Market
10.2.1 North America
10.2.1.1 U.S.
10.2.1.1.1 Domestic Production of Mo-99 in the U.S.
10.2.1.1.2 Approval of New Radiopharmaceuticals By Fda
10.2.1.2 Canada
10.2.1.2.1 Extension of Operations at the Canadian National Research Universal (NRU) Reactor
10.2.1.2.2 Alternative Medical Isotope Technologies in Canada
10.3 Therapeutic Market
10.3.1 North America
10.3.1.1 U.S.
10.3.1.1.1 Fda Approval for Alpha Emitter
10.3.1.1.2 Therapeutic Nuclear Medicine – Alternative Treatment Choice in Oncology
10.3.1.1.3 Growing Incidence of Thyroid Cancer
10.3.1.2 Canada
10.3.1.2.1 Expertise in Isotope Production
10.3.1.2.2 Government Initiatives to Increase the Number of Nuclear Medicine Treatment Centers
10.3.1.2.3 High Incidence of Cancer

11 Competitive Landscape (Page No. – 136)
11.1 Overview
11.2 Competitive Situation and Trends
11.2.1 Introduction
11.2.2 Agreements, Collaborations, Contracts, and Partnerships
11.2.3 Marketing and Promotions
11.2.4 New Product Launches
11.2.5 Expansions
11.2.6 Acquisitions
11.2.7 Other Strategies
11.3 North American Nuclear Medicine Market: Empirical Assessment of Growth Strategies
11.3.1 Route to Strategic Growth: Organic and Inorganic Growth Strategies
11.3.2 Organic Growth Strategies
11.3.3 Inorganic Growth Strategies

12 Company Profiles (Page No. – 147)
(Overview, Financials, Products & Services, Strategy, & Developments)*
12.1 Introduction
12.2 Cardinal Health, Inc.
12.3 Mallinckrodt PLC
12.4 GE Healthcare
12.5 Lantheus Medical Imaging, Inc.
12.6 Bayer Healthcare
12.7 Bracco Imaging S.P.A
12.8 Eczacibasi-Monrol Nuclear Products
12.9 Nordion, Inc.
12.10 Advanced Accelerator Applications S.A.
12.11 IBA Molecular Imaging

*Details on Financials, Product & Services, Strategy, & Developments Might Not Be Captured in Case of Unlisted Companies.

13 Appendix (Page No. – 169)
13.1 Discussion Guide
13.2 Available Customizations
13.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
13.4 Introducing RT: Real-Time Market Intelligence
13.5 Related Reports